Last reviewed · How we verify
Anti-hypertensive drugs
Anti-hypertensive drugs lower blood pressure through various mechanisms including vasodilation, reduced cardiac output, or decreased peripheral vascular resistance.
Anti-hypertensive drugs lower blood pressure through various mechanisms including vasodilation, reduced cardiac output, or decreased peripheral vascular resistance. Used for Hypertension (essential or secondary), Blood pressure reduction in cardiovascular disease prevention.
At a glance
| Generic name | Anti-hypertensive drugs |
|---|---|
| Sponsor | Universal Research Group |
| Drug class | Anti-hypertensive agent (class designation pending specific mechanism) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Anti-hypertensive drugs represent a broad class of medications that reduce blood pressure through multiple distinct mechanisms. Common approaches include blocking angiotensin II (ACE inhibitors, ARBs), inhibiting sympathetic nervous system activity (beta-blockers, alpha-blockers), promoting vasodilation (calcium channel blockers, nitrates), or increasing sodium and water excretion (diuretics). The specific mechanism depends on the drug subclass within this category.
Approved indications
- Hypertension (essential or secondary)
- Blood pressure reduction in cardiovascular disease prevention
Common side effects
- Dizziness or lightheadedness
- Fatigue
- Headache
- Cough (ACE inhibitor-specific)
- Hyperkalemia (ACE inhibitor/ARB-specific)
- Hypotension
Key clinical trials
- Effect of Hypertensive Drugs on Root Caries Among Senior Patients in Cairo University
- CENtral Blood Pressure Targeting: A Pragmatic RAndomized Pilot triaL in Advanced Chronic Kidney Disease (NA)
- REnin-guided TherApy With MinEralocorticoid Receptor Antagonists in Primary Aldosteronism - Feasibility Study (NA)
- The GUARDIAN Pilot Trial (NA)
- Unknown Time of Onset Stroke RePerfusIon Without Advanced Imaging (PHASE3)
- Intravenous Tenecteplase in Very Old Patients With Acute Ischemic Stroke
- Effect of Systemic Inflammatory Index and Systemic Immune Inflammation Index on Ecchymosis, Bleeding and Edema
- Triple Antihypertensive Medication After Intracerebral Hemorrhage for Blood Pressure Control (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anti-hypertensive drugs CI brief — competitive landscape report
- Anti-hypertensive drugs updates RSS · CI watch RSS
- Universal Research Group portfolio CI